177Lu-DOTA-TLX591
ProstACT TARGET
Phase 2 mab completed
Quick answer
177Lu-DOTA-TLX591 for Prostate Cancer is a Phase 2 program (mab) at Telix Pharmaceuticals Ltd with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Telix Pharmaceuticals Ltd
- Indication
- Prostate Cancer
- Phase
- Phase 2
- Modality
- mab
- Status
- completed